尼达尼布联合化疗治疗特发性肺纤维化合并非小细胞肺癌的随机III期试验
J-SONIC研究纳入243例化疗初治的晚期NSCLC合并IPF患者,随机接受卡铂联合白蛋白结合型紫杉醇±尼达尼布治疗。主要终点无急性加重生存期(EFS)未达统计学显著(HR 0.89,90%CI 0.67-1.17;p=0.24),但尼达尼布组中位无进展生存期(PFS)改善(HR 0.68,95%CI 0.50-0.92),且在非鳞癌和GAP I期患者中总生存期获益。
要点
- 尼达尼布联合化疗未显著延长EFS,但显著改善PFS(HR 0.68)。
- 非鳞癌患者总生存期获益(HR 0.61,95%CI 0.40-0.93)。
- GAP I期患者总生存期获益(HR 0.61,95%CI 0.38-0.98)。
核心结论
- 研究主要终点EFS未达到统计学显著性。
- 卡铂联合白蛋白结合型紫杉醇在晚期NSCLC合并IPF患者中有效且可耐受。
- 尼达尼布联合化疗改善非鳞癌患者的总生存期。
研究设计与样本
- 随机III期试验(J-SONIC),纳入化疗初治的晚期NSCLC合并IPF患者243例。
- 试验组接受尼达尼布(150 mg每日两次)联合卡铂(AUC 6,第1天)及白蛋白结合型紫杉醇(100 mg·m-2,第1、8、15天),每3周一次;对照组仅化疗。
- 主要终点为无急性加重生存期(EFS)。
主要发现
- 中位EFS:尼达尼布联合化疗组14.6个月 vs 化疗组11.8个月(HR 0.89,90%CI 0.67-1.17;p=0.24)。
- 中位PFS:尼达尼布联合化疗组6.2个月 vs 化疗组5.5个月(HR 0.68,95%CI 0.50-0.92)。
- 非鳞癌患者总生存期HR 0.61(95%CI 0.40-0.93),GAP I期患者HR 0.61(95%CI 0.38-0.98)。
- 240例患者中7例(2.9%)在研究治疗期间发生急性加重。
临床怎么用
- 卡铂联合白蛋白结合型紫杉醇可作为晚期NSCLC合并IPF患者的治疗选择。
- 尼达尼布联合化疗可能优先考虑用于非鳞癌或GAP I期患者以改善总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease implicated as an independent risk factor for lung cancer. However, optimal treatment for advanced lung cancer with IPF remains to be established. We performed a randomised phase 3 trial (J-SONIC) to assess the efficacy and safety of nintedanib plus chemotherapy (experimental arm) compared with chemotherapy alone (standard-of-care arm) for advanced nonsmall cell lung cancer (NSCLC) with IPF. METHODS: Chemotherapy-naïve advanced NSCLC patients with IPF were allocated to receive carboplatin (area under the curve of 6 on day 1) plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (100 mg·m-2 on days 1, 8 and 15) every 3 weeks with or without nintedanib (150 mg twice daily, daily). The primary end-point was exacerbation-free survival (EFS). RESULTS: Between May 2017 and February 2020, 243 patients were enrolled. Median EFS was 14.6 months in the nintedanib plus chemotherapy group and 11.8 months in the chemotherapy group (hazard ratio (HR) 0.89, 90% CI 0.67-1.17; p=0.24), whereas median progression-free survival was 6.2 and 5.5 months, respectively (HR 0.68, 95% CI 0.50-0.92). Overall survival was improved by nintedanib in patients with nonsquamous histology (HR 0.61, 95% CI 0.40-0.93) and in those at GAP (gender-age-physiology) stage I (HR 0.61, 95% CI 0.38-0.98). Seven (2.9%) out of 240 patients experienced acute exacerbation during study treatment. CONCLUSIONS: The primary end-point of the study was not met. However, carboplatin plus nab-paclitaxel was found to be effective and tolerable in advanced NSCLC patients with IPF. Moreover, nintedanib in combination with such chemotherapy improved overall survival in patients with nonsquamous histology.
引用
- Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. Eur Respir J. 2022. PMID: 35361630. doi:10.1183/13993003.00380-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。